N-(2-Hydroxypropyl)methacrylamide (
HPMA) copolymer-
doxorubicin (Dox) has already shown clinical activity in
breast cancer patients. Moreover, we have recently found that an
HPMA conjugate containing a combination of both Dox and the
aromatase inhibitor aminoglutethimide (AGM) shows significantly increased anti-tumour activity in vitro. To better understand the mechanism of action of
HPMA copolymer-AGM conjugates several models were used here to investigate their effect on cell growth and
aromatase inhibition. Cytotoxicity of
HPMA copolymer conjugates containing AGM, Dox and also the combination AGM-Dox was determined by MTT assay in MCF-7 and MCF-7ca cells.
Androstenedione (5 x 10(- 8) M) stimulates the growth of MCF-7ca cells. Both free AGM and
polymer-bound AGM (0.2-0.4 mg/ml) were shown to block this mitogenic activity. When MCF-7ca cells were incubated [(3)H]
androstenedione both AGM and
HPMA copolymer-GFLG-AGM (0.2 mg/ml AGM-equiv.) showed the ability to inhibit
aromatase. Although, free AGM was able to inhibit isolated human placental microsomal
aromatase in a concentration dependent manner,
polymer-bound AGM was not, suggesting that drug release is essential for activity of the conjugate.
HPMA copolymer conjugates containing
aromatase inhibitors have potential for the treatment of
hormone-dependant
cancers, and it would be particularly interesting to explore further as potential
therapies in post-menopausal women as components of combination
therapy.